Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Deferred Taxes (2016 - 2026)

Anika Therapeutics has reported Deferred Taxes over the past 16 years, most recently at $108000.0 for Q1 2026.

Quarterly Deferred Taxes rose 500.0% to $108000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $83000.0 through Mar 2026, down 2.35% year-over-year, with the annual reading at -$7000.0 for FY2025, 102.69% down from the prior year.
Deferred Taxes was $108000.0 for Q1 2026 at Anika Therapeutics, up from -$25000.0 in the prior quarter.
Over five years, Deferred Taxes peaked at $234000.0 in Q4 2024 and troughed at -$2.4 million in Q1 2023.
The 5-year median for Deferred Taxes is -$184000.0 (2024), against an average of -$660941.2.
Year-over-year, Deferred Taxes crashed 769.23% in 2023 and then surged 500.0% in 2026.
A 5-year view of Deferred Taxes shows it stood at -$1.8 million in 2022, then decreased by 3.6% to -$1.8 million in 2023, then skyrocketed by 112.7% to $234000.0 in 2024, then tumbled by 110.68% to -$25000.0 in 2025, then skyrocketed by 532.0% to $108000.0 in 2026.
Per Business Quant, the three most recent readings for ANIK's Deferred Taxes are $108000.0 (Q1 2026), -$25000.0 (Q4 2025), and $3000.0 (Q3 2025).